今日の臨床サポート

膵嚢胞

著者: 入澤篤志 獨協医科大学医学部 内科学(消化器)

監修: 下瀬川徹 みやぎ県南中核病院企業団

著者校正/監修レビュー済:2020/01/10
参考ガイドライン:
  1. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 17: 738-753, 2017. PMID:28735806.
  1. 膵仮性嚢胞の内視鏡治療ガイドライン2009. 膵臓 24: 571-593, 2009.
  1. 膵炎局所合併症(膵仮性嚢胞,感染性被包化壊死等)に対する診断・治療コンセンサス. 膵臓 29: 775-818, 2014.
  1. 膵癌診療ガイドライン(2019年版).金原出版,2019.
患者向け説明資料

概要・推奨   

  1. 膵嚢胞は、嚢胞を構成する上皮の有無により仮性嚢胞と真性嚢胞に大別され、さらには腫瘍性嚢胞と非腫瘍性嚢胞に分類される。
  1. 膵嚢胞が発見された患者には、大きさにかかわらず腫瘍性嚢胞の鑑別のために画像による精密検査を行うことが勧められる(推奨度2)。
  1. 膵嚢胞の精密診断には、造影CT、MRI(MRCP)、EUS(造影EUSを含む)が勧められる(推奨度2)。
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となりま
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となりま
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧
  1. 閲覧にはご契約が必要 となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧には
薬剤監修について:
オーダー内の薬剤用量は日本医科大学付属病院 薬剤部 部長 伊勢雄也 以下、林太祐、渡邉裕次、井ノ口岳洋、梅田将光による疑義照会のプロセスを実施、疑義照会の対象については著者の方による再確認を実施しております。
※薬剤中分類、用法、同効薬、診療報酬は、エルゼビアが独自に作成した薬剤情報であり、
著者により作成された情報ではありません。
尚、用法は添付文書より、同効薬は、薬剤師監修のもとで作成しております。
※薬剤情報の(適外/適内/⽤量内/⽤量外/㊜)等の表記は、エルゼビアジャパン編集部によって記載日時にレセプトチェックソフトなどで確認し作成しております。ただし、これらの記載は、実際の保険適用の査定において保険適用及び保険適用外と判断されることを保証するものではありません。また、検査薬、輸液、血液製剤、全身麻酔薬、抗癌剤等の薬剤は保険適用の記載の一部を割愛させていただいています。
(詳細はこちらを参照)
著者のCOI(Conflicts of Interest)開示:
入澤篤志 : 特に申告事項無し[2021年]
監修:下瀬川徹 : 特に申告事項無し[2021年]

改訂のポイント:
  1. 定期レビューを行い、各種ガイドラインの改定に基づいた改訂を行った。
  1. 各嚢胞性病変の画像診断について記載を詳細化した。

病態・疫学・診察

疾患情報(疫学・病態)  
  1. 膵嚢胞とは、膵臓あるいは周囲に嚢胞を形成するすべての疾患の総称であり、あくまで形態学的特徴に基づいた名称である。
  1. 以前は、膵管との交通のない袋状の構造物に限定されていたが、今日では膵管との交通の有無は問わない。
  1. 分類については以前から多数報告されている[1][2][3][4]が、膵嚢胞は、嚢胞を構成する上皮の有無により仮性嚢胞と真性嚢胞に大別され、さらには腫瘍性嚢胞と非腫瘍性嚢胞に分類される[5]
 
膵臓の嚢胞性病変

非腫瘍性嚢胞では、内腔に上皮を欠く仮性嚢胞が多く、次に膵管が拡張する貯留嚢胞が続く。良性の嚢胞性腫瘍の代表はSCNであり、膵管が拡張した病変であるIPMNでは良性あるいは悪性および前悪性の段階がある。このほか、充実性腫瘍の内部が変性し、嚢胞化を呈することがあり、代表はSPNと内分泌腫瘍である。

 
膵嚢胞の分類

内腔の上皮の有無で真性と仮性に分け、次に腫瘍性か非腫瘍性かを分ける分類が理解しやすい。

出典

img1:  [Pancreatic tumor: progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN): 6. Other cystic neoplasms of the pancreas].
 
 Nihon Naika Gakkai Zasshi. 2012 Jan 10;1・・・
 
  1. 近年の画像診断の普及および膵嚢胞性疾患概念の浸透により、膵嚢胞の発見頻度は増加している。最も頻度が高いのは仮性嚢胞と報告されている[2][3][4]。しかし最近ではIPMNの発見頻度が増加している。先天性の膵嚢胞はまれである。
  1. 炎症に伴う非腫瘍性嚢胞では、感染や出血を伴うことで腹痛・背部痛、発熱などを呈する。腫瘍性嚢胞においては、膵管の圧排狭窄、IPMNの粘液による膵管閉塞などにより急性膵炎を呈することがある。しかし、その他の嚢胞性病変では症状を有する例は少なく、検診や他疾患の精査中に偶然に発見されることも少なくない。
 
非腫瘍性嚢胞:
  1. 非腫瘍性嚢胞には、単純性嚢胞、貯留嚢胞、仮性嚢胞(急性/慢性)、類上皮嚢胞、類皮嚢胞、リンパ上皮嚢胞等がある。
  1. 2013年に急性膵炎後の局所合併症の概念がみなおされ,嚢胞性病変は急性仮性嚢胞と被包化膵壊死(walled-off necrosis:WON)に分類された[6]
 
改訂アトランタ分類における膵局所合併症の分類

急性膵炎後の仮性嚢胞・walled-off necrosisの発生形態と分類が示されている。
 
参考文献:
From Banks PA et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-11. PMID:23100216.

出典

img1:  著者提供
 
 
 
  1. 急性仮性嚢胞は、急性膵炎後に急性膵周囲液体貯留が時間の経過とともに被包化され、膵または周囲の壊死組織を含まずに嚢胞化したものである。一方、WONは壊死性膵炎に伴う浸出液貯留が、膵および周囲の壊死の液状化とともに被包化されたものである。
  1. 慢性仮性嚢胞は、慢性膵炎を背景として、膵管が破綻して膵液が貯留して形成されたもので、確実な壁をもち先行する急性膵炎発作を認めないものである[7]
  1. 貯留嚢胞や仮性嚢胞のなかには、膵癌などの充実性腫瘍によって膵管が狭窄・閉塞することが原因で嚢胞を形成する場合があり注意が必要である。
 
腫瘍性嚢胞:
腫瘍性膵嚢胞は、漿液性嚢胞腫瘍(serous cystic neoplasm、SCN)、粘液性嚢胞腫瘍(mucinous cystic neoplasm、MCN)、膵管内乳頭粘液性腫瘍(intraductal papillary-mucinous neoplasm、IPMN)が主なものである[5]。一方、充実性腫瘍が出血壊死等を来して内部が嚢胞変成を起こすものがある。代表的なものとしては、solid-pseudopapillary neoplasm(SPN)や神経内分泌腫瘍(neuroendocrine neoplasm, NEN)等が挙げられる[5]
問診・診察のポイント  
  1. 年齢、性別を確認する(SCNは中年女性に多く、MCNはほとんどが若年から中年女性、SPNは若年者に好発)。

これより先の閲覧には個人契約のトライアルまたはお申込みが必要です。

最新のエビデンスに基づいた二次文献データベース「今日の臨床サポート」。
常時アップデートされており、最新のエビデンスを各分野のエキスパートが豊富な図表や処方・検査例を交えて分かりやすく解説。日常臨床で遭遇するほぼ全ての症状・疾患から薬剤・検査情報まで瞬時に検索可能です。

まずは15日間無料トライアル
本サイトの知的財産権は全てエルゼビアまたはコンテンツのライセンサーに帰属します。私的利用及び別途規定されている場合を除き、本サイトの利用はいかなる許諾を与えるものでもありません。 本サイト、そのコンテンツ、製品およびサービスのご利用は、お客様ご自身の責任において行ってください。本サイトの利用に基づくいかなる損害についても、エルゼビアは一切の責任及び賠償義務を負いません。 また、本サイトの利用を以て、本サイト利用者は、本サイトの利用に基づき第三者に生じるいかなる損害についても、エルゼビアを免責することに合意したことになります。  本サイトを利用される医学・医療提供者は、独自の臨床的判断を行使するべきです。本サイト利用者の判断においてリスクを正当なものとして受け入れる用意がない限り、コンテンツにおいて提案されている検査または処置がなされるべきではありません。 医学の急速な進歩に鑑み、エルゼビアは、本サイト利用者が診断方法および投与量について、独自に検証を行うことを推奨いたします。

文献 

著者: Mohammad Al-Haddad, Max C Schmidt, Kumar Sandrasegaran, John Dewitt
雑誌名: Clin Gastroenterol Hepatol. 2011 Aug;9(8):635-48. doi: 10.1016/j.cgh.2011.03.005. Epub 2011 Mar 11.
Abstract/Text Cystic pancreatic tumors (CPTs) have more frequently been identified in the last decade because of increased use of cross-sectional abdominal imaging. Although serous CPTs follow an indolent course and do not necessarily require surgical resection or long-term follow-up, mucinous CPTs (mucinous cystic neoplasms and intraductal papillary mucinous neoplasms) have a greater risk for malignancy. Although most CPTs are initially detected with imaging modalities such as computed tomography or magnetic resonance imaging, these tests alone rarely permit an accurate clinical diagnosis. Endoscopic ultrasound and endoscopic ultrasound-guided, fine-needle aspiration allow real-time examination and biopsy analysis of CPTs, which increases diagnostic accuracy because cytopathology features and tumor markers in cyst fluid can be analyzed. Management of patients with mucinous CPTs by surgery or imaging surveillance is controversial, partially because of limited information about disease progression and the complexities of surgical resection. We review approaches to diagnosis and management of common CPTs.

Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
PMID 21397725  Clin Gastroenterol Hepatol. 2011 Aug;9(8):635-48. doi: ・・・
著者: Josefin Björk Werner, Anna Bartosch-Härlid, Roland Andersson
雑誌名: Scand J Gastroenterol. 2011 Jul;46(7-8):773-88. doi: 10.3109/00365521.2011.551892. Epub 2011 Feb 3.
Abstract/Text Pancreatic cystic neoplasms are detected at an increasing frequency due to an increased use and quality of abdominal imaging. There are well known differential diagnostic difficulties concerning these lesions. The aim is to review current literature on the diagnostic options and the following treatment for cystic lesions in the pancreas focusing on serous cystadenomas, primary mucinous neoplasm of the pancreas and mucinous cystadenocarcinomas, as well as intraductal papillary mucinous neoplasms, starting with excluding pseudocysts. A conservative approach is feasible in patients with a clinical presentation suggestive of an asymptomatic serous cystadenoma. Surgical management, as well as follow-up, is discussed for each of the types of neoplastic lesions, including an uncharacterized cyst, based on patient data, symptoms, serum analysis, cyst fluid analysis and morphological features. Aspects for future diagnostics and management of these neoplasia are commented upon.

PMID 21288141  Scand J Gastroenterol. 2011 Jul;46(7-8):773-88. doi: 10・・・
著者: G Garcea, S L Ong, A Rajesh, C P Neal, C A Pollard, D P Berry, A R Dennison
雑誌名: Pancreatology. 2008;8(3):236-51. doi: 10.1159/000134279. Epub 2008 May 23.
Abstract/Text BACKGROUND/AIMS: Due to enhanced imaging modalities, pancreatic cysts are being increasingly detected, often as an incidental finding. They comprise a wide range of differing underlying pathologies from completely benign through premalignant to frankly malignant. The exact diagnostic and management pathway of these cysts remains problematic and this review attempts to provide an overview of the pathology underlying pancreatic cystic lesions and suggests appropriate methods of management.
METHODS: A search was undertaken with a Pubmed database to identify all English articles using the keywords 'pancreatic cysts', 'serous cystadenoma', 'intraductal papillary mucinous tumour', 'pseudocysts', 'mucinous cystic neoplasm' and 'solid pseudopapillary tumour'.
RESULTS: The mainstay of assessment of pancreatic cysts is cross-sectional imaging incorporating CT and MRI. Fine-needle aspiration (FNA) (often with endoscopic ultrasound) may provide valuable additional information but can lack sensitivity. Symptomatic cysts, increasing age and multilocular cysts (with a solid component and thick walls) are predictors of malignancy. A raised cyst aspirate CEA, CA 19-9 and mucin content (including abnormal cytology), if present, can accurately distinguish premalignant and malignant cysts from benign ones.
CONCLUSION: In summary, all patients with pancreatic cystic lesions, whether asymptomatic or symptomatic, must be thoroughly investigated to ascertain the underlying nature of the cyst. Small asymptomatic cysts (<3 cm) with no suspicious features on imaging or FNA may be safely followed up. Follow-up should continue for at least 4 years, with a repeat FNA if needed. An algorithm for the management of pancreatic cystic tumours is also suggested. and IAP.

Copyright 2008 S. Karger AG, Basel.
PMID 18497542  Pancreatology. 2008;8(3):236-51. doi: 10.1159/000134279・・・
著者: Hiroyuki Maguchi, Manabu Osanai, Akio Katanuma, Kuniyuki Takahashi
雑誌名: Nihon Naika Gakkai Zasshi. 2012 Jan 10;101(1):93-9. doi: 10.2169/naika.101.93.
Abstract/Text
PMID 22413466  Nihon Naika Gakkai Zasshi. 2012 Jan 10;101(1):93-9. doi・・・
著者: Peter A Banks, Thomas L Bollen, Christos Dervenis, Hein G Gooszen, Colin D Johnson, Michael G Sarr, Gregory G Tsiotos, Santhi Swaroop Vege, Acute Pancreatitis Classification Working Group
雑誌名: Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.
Abstract/Text BACKGROUND AND OBJECTIVE: The Atlanta classification of acute pancreatitis enabled standardised reporting of research and aided communication between clinicians. Deficiencies identified and improved understanding of the disease make a revision necessary.
METHODS: A web-based consultation was undertaken in 2007 to ensure wide participation of pancreatologists. After an initial meeting, the Working Group sent a draft document to 11 national and international pancreatic associations. This working draft was forwarded to all members. Revisions were made in response to comments, and the web-based consultation was repeated three times. The final consensus was reviewed, and only statements based on published evidence were retained.
RESULTS: The revised classification of acute pancreatitis identified two phases of the disease: early and late. Severity is classified as mild, moderate or severe. Mild acute pancreatitis, the most common form, has no organ failure, local or systemic complications and usually resolves in the first week. Moderately severe acute pancreatitis is defined by the presence of transient organ failure, local complications or exacerbation of co-morbid disease. Severe acute pancreatitis is defined by persistent organ failure, that is, organ failure >48 h. Local complications are peripancreatic fluid collections, pancreatic and peripancreatic necrosis (sterile or infected), pseudocyst and walled-off necrosis (sterile or infected). We present a standardised template for reporting CT images.
CONCLUSIONS: This international, web-based consensus provides clear definitions to classify acute pancreatitis using easily identified clinical and radiologic criteria. The wide consultation among pancreatologists to reach this consensus should encourage widespread adoption.

PMID 23100216  Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-30・・・
著者: Atsushi Irisawa, Ai Sato, Masaki Sato, Tsunehiko Ikeda, Rei Suzuki, Hiromasa Ohira
雑誌名: Dig Endosc. 2009 Jul;21 Suppl 1:S92-6. doi: 10.1111/j.1443-1661.2009.00866.x.
Abstract/Text Advanced pancreatic cancer is a major cause of cancer-related death. However, if surgery achieves clear margins and negative lymph nodes, the prognosis for survival can be prolonged. Therefore, early diagnosis - as early as possible - is important for improving overall survival and quality of life in patients with pancreatic cancer. Because of higher imaging resolution near the pancreas through the gastroduodenal wall, endoscopic ultrasonography enables detection of subtle pancreatic abnormalities. In fact, many investigators have reported the high ability of EUS not only for detection of small lesions but also recognition of chronic pancreatitis, which is the risky status of pancreatic cancer. As a tool for early diagnosis of pancreatic cancer, EUS is a highly anticipated modality.

PMID 19691746  Dig Endosc. 2009 Jul;21 Suppl 1:S92-6. doi: 10.1111/j.1・・・
著者: Ken Kamata, Masayuki Kitano, Masatoshi Kudo, Hiroki Sakamoto, Kumpei Kadosaka, Takeshi Miyata, Hajime Imai, Kiyoshi Maekawa, Takaaki Chikugo, Masashi Kumano, Tomoko Hyodo, Takamichi Murakami, Yasutaka Chiba, Yoshifumi Takeyama
雑誌名: Endoscopy. 2014 Jan;46(1):22-9. doi: 10.1055/s-0033-1353603. Epub 2013 Nov 11.
Abstract/Text BACKGROUND AND STUDY AIMS: Pancreatic ductal adenocarcinomas (PDAC) sometimes arise in patients with intraductal papillary mucinous neoplasms (IPMNs). This study examined the incidence of PDACs concomitant to or derived from branch duct IPMNs. The usefulness of endoscopic ultrasonography (EUS) relative to other imaging methods for detecting these tumors was also assessed.
PATIENTS AND METHODS: This retrospective study used data from clinical records and imaging studies that were collected prospectively. During 2001-2009, 167 consecutive patients with IPMNs underwent EUS, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). The 102 patients whose branch duct IPMNs lacked mural nodules/symptoms and thus did not qualify for resection were followed up by semiannual EUS and annual ultrasonography, CT, and MRI. The sensitivity and specificity with which the four modalities detected IPMN-derived and -concomitant PDACs at the first examination and throughout the study period were evaluated. The rate of PDAC development during follow-up was analyzed by the Kaplan-Meier method.
RESULTS: A total of 17 IPMN-derived and 11 IPMN-concomitant PDACs were diagnosed at the first examination. Lesions that did not qualify for resection or chemotherapy were followed up for a median of 42 months. Seven IPMN-concomitant PDACs and no IPMN-derived PDACs were detected during follow-up. The 3- and 5-year rates of IPMN-concomitant PDAC development were 4.0% and 8.8%, respectively. At the first examination, EUS was superior to other imaging modalities in terms of IPMN-derived and -concomitant PDAC detection. Throughout the study period, including follow-up, EUS was significantly better at detecting IPMN-concomitant PDACs than the other modalities.
CONCLUSIONS: IPMN-concomitant PDACs are quite often found at diagnosis and during follow-up. EUS examination of the whole pancreas plays an important role in the management of IPMNs as it allows the early detection of these small invasive carcinomas.

© Georg Thieme Verlag KG Stuttgart · New York.
PMID 24218310  Endoscopy. 2014 Jan;46(1):22-9. doi: 10.1055/s-0033-135・・・
著者: Masao Tanaka, Carlos Fernández-Del Castillo, Terumi Kamisawa, Jin Young Jang, Philippe Levy, Takao Ohtsuka, Roberto Salvia, Yasuhiro Shimizu, Minoru Tada, Christopher L Wolfgang
雑誌名: Pancreatology. 2017 Sep - Oct;17(5):738-753. doi: 10.1016/j.pan.2017.07.007. Epub 2017 Jul 13.
Abstract/Text The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In particular, the indications for resection of branch duct IPMN have changed from early resection to more deliberate observation as proposed by the international consensus guidelines of 2006 and 2012. Another guideline proposed by the American Gastroenterological Association in 2015 restricted indications for surgery more stringently and recommended physicians to stop surveillance if no significant change had occurred in a pancreatic cyst after five years of surveillance, or if a patient underwent resection and a non-malignant IPMN was found. Whether or not it is safe to do so, as well as the method and interval of surveillance, has generated substantial debate. Based on a consensus symposium held during the meeting of the International Association of Pancreatology in Sendai, Japan, in 2016, the working group has revised the guidelines regarding prediction of invasive carcinoma and high-grade dysplasia, surveillance, and postoperative follow-up of IPMN. As the working group did not recognize the need for major revisions of the guidelines, we made only minor revisions and added most recent articles where appropriate. The present guidelines include updated information and recommendations based on our current understanding, and highlight issues that remain controversial or where further research is required.

Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.
PMID 28735806  Pancreatology. 2017 Sep - Oct;17(5):738-753. doi: 10.10・・・
著者: Shigetaka Yoshinaga, Takao Itoi, Kenji Yamao, Ichiro Yasuda, Atsushi Irisawa, Hiroshi Imaoka, Takayoshi Tsuchiya, Shinpei Doi, Akane Yamabe, Yoshitaka Murakami, Hideki Ishikawa, Yutaka Saito
雑誌名: Dig Endosc. 2019 Jun 5;. doi: 10.1111/den.13457. Epub 2019 Jun 5.
Abstract/Text OBJECTIVES: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for solid pancreatic lesions has high diagnostic yield. However, few prospective multicenter studies have been performed. We performed a prospective cohort study to evaluate the efficacy and safety of EUS-FNA for diagnosis of solid pancreatic lesions.
METHODS: This prospective cohort study involved five hospitals in Japan. The primary outcome was sensitivity of EUS-FNA for diagnosing malignant lesions. We also evaluated parameters of diagnostic sufficiency and the safety of EUS-FNA.
RESULTS: In total, 246 patients were enrolled. The absolute values of the parameters evaluated showed no significant differences; however, the percentage changes in the white blood cell counts and C-reactive protein levels after examination were significantly higher, and the percentage change in hemoglobin concentrations was significantly lower. The minor and major complication rates at the time of puncture, 24 h, 7 days and 28 days were 4.1%, 2.8%, 1.6%, and 0.0%, respectively. The true complication rate was 1.2%. The diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 97.2%, 88.0%, 96.2%, 100%, and 81.4%, respectively.
CONCLUSIONS: EUS-FNA for solid pancreatic lesions has high diagnostic yield and is safe, consistent with previously studies.

© 2019 Japan Gastroenterological Endoscopy Society.
PMID 31166046  Dig Endosc. 2019 Jun 5;. doi: 10.1111/den.13457. Epub 2・・・
著者: Atsushi Irisawa, Hironao Miyoshi, Takao Itoi, Shomei Ryozawa, Mitsuhiro Kida, Kazuo Inui
雑誌名: Dig Endosc. 2019 Jun 26;. doi: 10.1111/den.13473. Epub 2019 Jun 26.
Abstract/Text The development of endoscopic treatment for pancreatobiliary diseases in recent years is remarkable. In addition to conventional transpapillary treatments under endoscopic retrograde cholangiopancreatography (ERCP), new endoscopic ultrasound-guided therapy is being developed and implemented. On the other hand, due to the development/improvement of various devices such as new metal stents, a new therapeutic strategy under ERCP is also advocated. The present review focuses on recent advances in the endoscopic treatment of pancreatic pseudocysts, walled-off necrosis, malignant biliary strictures, and benign biliary/pancreatic duct strictures.

© 2019 Japan Gastroenterological Endoscopy Society.
PMID 31240746  Dig Endosc. 2019 Jun 26;. doi: 10.1111/den.13473. Epub ・・・
著者: Hiroyuki Maguchi, Satoshi Tanno, Nobumasa Mizuno, Keiji Hanada, Go Kobayashi, Takashi Hatori, Yoshihiko Sadakari, Taketo Yamaguchi, Kosuke Tobita, Ryuichiro Doi, Akio Yanagisawa, Masao Tanaka
雑誌名: Pancreas. 2011 Apr;40(3):364-70. doi: 10.1097/MPA.0b013e31820a5975.
Abstract/Text OBJECTIVE: The aim of this study was to evaluate the long-term follow-up results of patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) without mural nodules (MNs) at 10 representative institutions in Japan.
METHODS: We analyzed 349 follow-up BD-IPMN patients who had no MNs on endoscopic ultrasonography at initial diagnosis.
RESULTS: Observation periods ranged from 1 to 16.3 years (median, 3.7 years). Sixty-two (17.8%) patients exhibited disease progression during follow-up. Twenty-two underwent surgery, leading to a pathological diagnosis of carcinoma in 9 and adenoma in 13. Although the remaining 287 (82.2%) showed no changes, 7 underwent surgery because of symptoms (n = 2), choice (n = 2), or development of pancreatic ductal adenocarcinoma (n = 3); all of them were diagnosed pathologically as adenomas. Of the 29 patients undergoing surgery, all 9 with carcinoma exhibited signs of progression, such as increased main pancreatic duct diameter and/or appearance of MNs. Pancreatic ductal adenocarcinomas and additional BD-IPMNs developed in 7 (2.0%) and 13 (3.7%), respectively. Overall, 320 (91.7%) patients were followed without surgery.
CONCLUSIONS: Most BD-IPMN patients who had no MNs on endoscopic ultrasonography could be managed without surgery. However, careful attention should be paid to disease progression and the development of pancreatic ductal adenocarcinomas during follow-up.

PMID 21289527  Pancreas. 2011 Apr;40(3):364-70. doi: 10.1097/MPA.0b013・・・
著者: Mitsuharu Fukasawa, Hiroyuki Maguchi, Kuniyuki Takahashi, Akio Katanuma, Manabu Osanai, Akira Kurita, Tamaki Ichiya, Takayoshi Tsuchiya, Toshifumi Kin
雑誌名: Pancreatology. 2010;10(6):695-701. doi: 10.1159/000320694. Epub 2011 Jan 18.
Abstract/Text AIMS: To clarify the clinical features and the natural history of serous cystic neoplasm (SCN) of the pancreas.
METHODS: We retrospectively analyzed data from 30 patients affected by SCN. SCNs were classified as (1) microcystic type, (2) micro- and macrocystic type, and (3) macrocystic type according to the modified WHO classification. Eighteen patients who underwent serial radiographic imaging were identified, and tumor growth rate in these patients was evaluated.
RESULTS: The median age was 62 years, and the female:male ratio was 2:1. Twenty-five patients (83%) were asymptomatic and 5 (17%) were symptomatic. The median tumor size was 2.6 cm. Fifteen cases (50%) had the microcystic type, 7 (23%) the micro- and macrocystic type, and 8 (27%) the macrocystic type. Age, gender, symptoms, location or tumor size did not differ significantly among the three subtypes. Eighteen patients were followed up for a median of 58 months. Morphological changes were observed in 3 patients (17%) and enlargement of tumor size in 9 patients (50%) during the follow-up. The growth rate was 0.29 cm per year and doubling time was 3.5 years; these rates did not differ among morphological subtypes or size of tumors.
CONCLUSIONS: In asymptomatic patients with a clear imaging diagnosis of SCN, nonoperative management with a careful follow-up should be recommended. Surgery should be suggested in only symptomatic patients, those with giant tumors (>10 cm), rapid growing or when the presence of a potentially malignant tumor cannot be excluded. and IAP.

Copyright © 2011 S. Karger AG, Basel.
PMID 21242709  Pancreatology. 2010;10(6):695-701. doi: 10.1159/0003206・・・

ページ上部に戻る

戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから